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Abstract 
Background: Despite the recent development of new therapies, multiple myeloma (MM) remains an incurable 
disease. Thus, new, effective treatments are urgently needed, particularly for relapsed or refractory MM (RRMM). In an 
earlier phase I study, a novel form of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) that is currently in clinical development for the treatment of hematologic malignancies, i.e., circularly 
permuted TRAIL (CPT), was well tolerated at a dose of 2.5 mg/kg per day and showed promising preliminary activity in 
patients with RRMM. This phase II, open-label, multicenter study further investigated the efficacy and safety of 2.5-mg/
kg per day CPT as single-agent therapy for patients with RRMM.
Methods: Patients with RRMM were treated once daily with CPT (2.5 mg/kg, intravenously) for 14 consecutive days 
for each 21-day cycle. Clinical response and toxicity were assessed after each treatment cycle.
Results: Twenty-seven patients received CPT. Using the European Group for Blood and Marrow Transplantation 
criteria, we calculated the overall response rate of 33.3% with 1 near-complete response (nCR) and 8 partial responses 
(PRs). The clinical benefit rate (48.1%) included 1 nCR, 8 PRs, and 4 minimal responses. The most common treatment-
related adverse events (TRAEs) were fever, aspartate aminotransferase elevation, alanine aminotransferase elevation, 
leucopenia, rash, neutropenia, and thrombocytopenia. We graded toxicity using the Common Toxicity Criteria for 
Adverse Events, version 3.0, and determined that 37.0% of patients had at least 1 grade 3–4 TRAE.
Conclusions: CPT as a single agent can elicit a response in patients with RRMM and is well tolerated. Further clinical 
investigation is warranted.
Trial Registration ChiCTR-ONC-12002065 http://www.chictr.org/cn
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Background
Multiple myeloma (MM) is a malignancy of mature 
plasma cells. In the United States, it is the second most 
common hematologic malignancy. Recently, new treat-
ments, including autologous stem cell transplantation, 
proteasome inhibitors (e.g., bortezomib), and immu-
nomodulatory drugs (IMiDs; e.g., thalidomide and lena-
lidomide), have substantially improved the response and 
survival rates of patients with MM [1]. However, relapse 
and drug resistance remain inevitable. Therefore, addi-
tional novel and more effective treatments are urgently 
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needed for patients with relapsed or refractory MM 
(RRMM).
In 1995, apoptosis ligand 2/tumor necrosis factor-
related apoptosis-inducing ligand (Apo2L/TRAIL) was 
discovered as a new member of the tumor necrosis fac-
tor superfamily [2]. It binds to death receptor 4 (DR4) 
and death receptor 5 (DR5) on the cell surface to form 
the death-inducing signaling complex, thereby activating 
the caspase cascade to induce apoptosis, a signaling event 
known as the extrinsic apoptotic pathway [3]. Apo2L/
TRAIL selectively and quickly induces cell apoptosis in 
many solid tumors and hematologic malignancies, while 
exhibiting no toxicity to normal cells [4, 5].
Circularly permuted TRAIL (CPT) is a novel mutant 
form of recombinant human Apo2L/TRAIL that is cur-
rently in clinical development for the treatment of MM 
and other hematologic malignancies. The primary 
molecular feature of CPT is amino acid (aa) 121–135 at 
the N-terminus of wild-type Apo2L/TRAIL, which is 
connected to aa 135–281 at its C-terminus via a flexible 
linker. Consequently, compared with wild-type Apo2L/
TRAIL, CPT has better stability, demonstrates more 
potent anti-tumor activity, and has a slightly longer 
in vivo half-life in mice, rats, and humans [6].
For pretreated patients with either hematologic malig-
nancies (including lymphoma and MM) or advanced 
solid tumors (e.g., lung, colorectal, and renal cancers), a 
phase I study (unpublished data) evaluated the safety of 
CPT monotherapy by single-dose escalation (0.5–3.5 mg/
kg) and by multiple-dose escalation (1.0–2.5  mg/kg). In 
the multiple-dose escalation, CPT was administered once 
daily for 14 consecutive days for each 21-day cycle. Unex-
pectedly, 2 of 3 patients with RRMM achieved a partial 
response after the first cycle of CPT treatment at the 2.5-
mg/kg dose. This early evidence of activity of single-agent 
CPT in patients with RRMM caused the dose-escalation 
study to be terminated, while the maximum tolerated 
dose (MTD) was not reached. MTD was defined as the 
highest dose level at which 33% or fewer patients expe-
rienced a dose-limiting toxicity (DLT), according to the 
3+3 design. DLT was predefined as any of the following 
that occurred during the first course of treatment and 
was determined to be possibly, probably, or definitely 
related to study treatment: (a) grade 3 or higher non-
hematologic toxicities and (b) grade 4 hematologic toxic-
ity. In this phase I trial of 28 patients, the most common 
treatment-related adverse events (TRAEs) were alanine 
aminotransferase (ALT) elevation (42.9%),
aspartate aminotransferase (AST) elevation (32.1%), 
fever (14.3%), fatigue (10.7%), nausea (10.7%), and vom-
iting (10.7%). Of these TRAEs, 14.3% were grade 3 or 
4, all were associated with hepatotoxicity, and all were 
resolved by treating the symptoms or discontinuing CPT 
treatment (unpublished data).
Preliminary results suggested that single-agent CPT, 
given at a well-tolerated dose of 2.5 mg/kg, once daily for 
14 consecutive days for each 21-day cycle, has promising 
anti-tumor activity in patients with RRMM. Accordingly, 
this dose and schedule was then chosen as the recom-
mended dose for the current phase II trial that targets 
a cohort of patients with RRMM only. Therefore, our 
phase II, single-arm, open-label, multicenter clinical trial 
further evaluated the safety and efficacy of single-agent 
CPT, given at 2.5 mg/kg once daily for 14 days for each 
21-day cycle, in patients with RRMM.
Patients and methods
Ethics
The study was approved by the Institutional Review 
Boards of all participating institutions, including Bei-
jing Chao-Yang Hospital (Capital Medical University), 
Institute of Hematology and Blood Diseases Hospital 
(Chinese Academy of Medical Science & Peking Union 
Medical College), Shanghai Changzheng Hospital (the 
Second Military Medical University), and the Second 
Hospital of Hebei Medical University. Informed consent 
was obtained from each patient. The clinical trial regis-
tration id is ChiCTR-ONC-12002065.
Patient eligibility
To be eligible for the study, patients with measurable 
MM must have received at least one prior treatment 
before relapse or becoming refractory to the prior treat-
ment. Additional inclusion criteria included (a) at least 
18 years of age; (b) a white blood cell count of 2.0 × 109/L 
or higher, a neutrophil count of 1.0 × 109/L or higher, a 
platelet count of 30 × 109/L or higher, and a hemoglobin 
count of 60 g/L or higher; (c) total serum bilirubin, ALT, 
and AST levels each 1.25 times or below the upper lim-
its of normal; (d) a Karnofsky Performance Status score 
of 60 or higher; and (e) an expected survival time of 
3 months or longer.
Exclusion criteria included pregnancy; lactation; his-
tory of allergic reactions to proteins or other biological 
products; an allergic constitution; previous history of 
viral hepatitis, cirrhosis, alcoholic liver disease, or drug-
induced hepatitis (based on the observation that hepa-
totoxicity was commonly observed in the phase I trial of 
single-agent CPT); congestive heart failure (New York 
Heart Association Functional Class III–IV); symptomatic 
ischemia; conduction abnormalities uncontrolled by 
conventional intervention; myocardial infarction within 
6  months of first dose; other tumors; or deemed other-
wise unsuitable by the investigators.
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Study design and treatment
For our study, we used the standard single-stage design 
[7]. This design requires at least 27 patients to test 
the null hypothesis that the true overall response rate 
(ORR) for CPT treatment is at most 5% versus the alter-
native hypothesis that the largest true ORR is 20% or 
more with a one-sided α of 0.05 and power (1 −  β) of 
0.8.
CPT (5 mg/vial) was provided as a lyophilized prepara-
tion. The drug was dissolved in 250 mL of 5% glucose. It 
was then administered at a dose of 2.5 mg/kg via continu-
ous intravenous infusion over 90 ± 15 min once daily for 
14 consecutive days for each 21-day cycle, for a total of 
two cycles.
Assessments and endpoints
We assessed therapeutic response at the end of each 
treatment cycle. Serum levels of the involved immuno-
globulins were determined by nephelometry, and urine 
levels of M-protein were determined by the 24-hour 
urine tests that measure kappa and lambda light chain. 
Therapeutic responses were defined as complete 
response (CR), near-complete response (nCR), par-
tial response (PR), minimal response (MR), no change 
(NC), and progressive disease (PD), according to the 
European Group for Blood and Marrow Transplantation 
criteria [8].
Adverse events were monitored throughout the 
study and recorded for all patients who received at 
least one dose of CPT. Adverse event data were col-
lected at the four participating institutions from inves-
tigator reports and patient self-reports. Adverse events 
were graded according to the Common Toxicity Crite-
ria for Adverse Events, version 3.0. Other safety assess-
ments included clinical laboratory tests and vital sign 
observations. Using the indirect enzyme linked immu-
nosorbent assay (ELISA) test, CPT immunogenicity 
was evaluated by detecting serum anti-CPT antibodies 
(IgG or IgM).
Study endpoints were therapeutic response rates, 
including ORR (defined as the percentage of patients who 
achieved CR, nCR, or PR) and clinical benefit rate (CBR; 
defined as the percentage of patients who achieved CR, 
nCR, PR, or MR), and adverse event incidences.
Statistical analysis
Student’s t test was used for comparing measurement 
data; the Chi square test or Fisher’s exact test was used 
for comparing enumeration data. All statistical analyses 
were two-sided. P values less than or equal to 0.05 were 
considered statistically significant. Statistical analyses 




At four participating institutions in China, 27 patients 
(9 women and 18 men) were enrolled between septem-
ber 2007 and october 2008. Patient characteristics are 
summarized in Table 1. The median age of patients was 
56 years. The median time from diagnosis was 21 months. 
The median number of prior treatments was 3. More 
than 85% of patients had previously received glucocor-
ticoids (25 patients) or alkylating agents (23 patients), 
and 14 patients (51.9%) and 21 patients (77.8%) had 
received prior bortezomib and IMiD (e.g., thalidomide 
Table 1 Baseline characteristics of  27 patients with  rela-
psed or refractory multiple myeloma (RRMM)
ISS international staging system, IMiDs immunomodulatory drugs
a These values are presented as median followed by ranges in the parentheses; 
other values are presented as number of patients followed by percentages in the 
parentheses
b Baseline β2-microglobulin was not determined in one patient; who could not 
be grouped into any ISS stage
Characteristic No. of patients (%)
Agea (years) 56 (36–77)
Sex
 Men 18 (66.7)
 Women 9 (33.3)
ISS stageb
 I 6 (23.1)
 II 14 (53.8)
 III 6 (23.1)
Time since diagnosisa (months) 21 (4–60)
Subtype of disease
 IgG 11 (40.7)
 IgA 6 (22.2)
 IgD 5 (18.5)
 Light chain 5 (18.5)
β2-microglobulinb
 Levela (mg/L) 3.4 (1.1–16.7)
 <3.5 mg/L 14 (53.8)
 ≥3.5 mg/L 12 (46.2)
Prior therapy
 Numbera (cycles) 3 (1–8)
 0–3 cycles 14 (51.9)
 >3 cycles 13 (48.1)
Prior regimen
 Glucocorticoids 25 (92.6)
 Alkylating agents 23 (85.2)
 IMiDs (thalidomide or lenalidomide) 21 (77.8)
 Vincristine 19 (70.3)
 Bortezomib 14 (51.9)
 Both bortezomib and IMiDs 9 (33.3)
 Autologous stem cell transplantation 5 (18.5)
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and lenalidomide) therapy, respectively. Using the Inter-
national Staging System, 74.1% (20 of 27) of patients were 
diagnosed with stage II/III MM.
Efficacy
All 27 patients were evaluated for therapeutic responses 
to single-agent CPT. As shown in Table 2, the ORR was 
33.3% (9 of 27), in which 1 patient achieved an nCR 
and 8 patients achieved a PR; additionally, 4 patients 
achieved an MR, resulting in a 48.1% (13 of 27) CBR 
(nCR + PR + MR). Three (11.1%) patients and 11 (40.7%) 
patients had NC and PD, respectively.
Post hoc analysis was then carried out to compare 
ORR or CBR between the subgroups divided upon differ-
ent baseline characteristics. Patients with baseline serum 
β2-microglobulin levels of 3.5  mg/L or higher (n  =  12) 
had an ORR of 50.0% and a CBR of 66.7% that were clearly 
higher than those for patients with serum β2-microglobulin 
levels lower than 3.5  mg/L (n  =  14) (ORR, 14.3%; CBR, 
28.6%); the β2-microglobulin level for the remaining 
one patient was not available. Interestingly, patients who 
received more than three prior therapies (n = 13) had an 
ORR of 46.2% and a CBR of 61.5% that were higher than 
those of patients who received three or fewer prior thera-
pies (n = 14) (ORR, 21.4%; CBR, 35.7%). Moreover, patients 
who received prior bortezomib treatment and then became 
resistant to or intolerant of bortezomib (n  =  14) had a 
higher ORR of 42.9% and CBR of 57.1% than patients who 
were not treated previously with bortezomib (n  =  13) 
(ORR, 23.1%; CBR, 38.5%). In addition, the ORR and CBR 
of patients who had previously received both bortezomib 
and IMiDs (n  =  9) were 33.3% and 55.5%, respectively. 
However, while all of the differences in ORR and CBR 
between these subgroups of patients with different base-
line characteristics were noteworthy, they were not statis-
tically significant (P  >  0.05 for all comparisons described 
above). These findings suggest that single-agent CPT is 
an effective treatment for patients with RRMM, including 
those patients who have been aggressively treated previ-
ously with regimens containing new agents such as bort-
ezomib and IMiDs.
Safety
All 27 patients received at least one cycle of CPT treat-
ment; of them, 21 (77.8%) completed two cycles of treat-
ment. Treatment was discontinued after the first cycle in 
only 6 patients; of these discontinuations, 4 were because 
of adverse events, and 2 were because of disease progres-
sion. These results suggest that single-agent CPT is well 
tolerated in patients with RRMM.
Regardless of whether adverse events were related 
to CPT treatment, the most common events (defined 
as incidence in  ≥10% of patients) were AST elevation 
(63.0%), fever (59.3%), ALT elevation (55.6%), leucopenia 
(48.2%), thrombocytopenia (25.9%), neutropenia (18.5%), 
upper respiratory infection (18.5%), anemia (14.8%), 
rash (14.8%), fatigue (14.8%), hypokalemia (11.1%), lac-
tate dehydrogenase (LDH) elevation (11.1%), pneumonia 
(11.1%), cough (11.1%), pharyngitis (11.1%), abdominal 
pain (11.1%), and diarrhea (11.1%). As shown in Table 3, 
the most common TRAEs were fever (48.1%), AST eleva-
tion (48.1%), ALT elevation (44.4%), leucopenia (25.9%), 
Table 2 Therapeutic responses of  27 RRMM patients 
to single-agent circularly permuted TRAIL (CPT) treatment
ORR overall response rate, CBR clinical benefit rate, TRAIL tumor necrosis factor-
related apoptosis-inducing ligand
a Responses were assessed according to the European Group for Blood and 
Marrow Transplantation criteria
Responsea No. of patients (%)
Near-complete response (nCR) 1 (3.7)
Partial response (PR) 8 (29.6)
Minimal response (MR) 4 (14.8)
No change (NC) 3 (11.1)
Progressive disease (PD) 11 (40.7)
ORR (nCR + PR) 9 (33.3)
CBR (nCR + PR + MR) 13 (48.1)
Table 3 Incidences of  treatment-related adverse eventsa 
after  single-agent CPT treatment in  27 patients with   
RRMM
Only those toxicities deemed possibly, probably, or definitely related to the 
treatment are included in the table. Note: a patient may have had more than one 
adverse event
AST aspartate aminotransferase, ALT alanine aminotransferase
a Adverse events were assessed according to the Common Toxicity Criteria 
for Adverse Events. Data are presented as number of patients followed by 
percentage in the parentheses
b Adverse event reported in at least 5% of the treated patients
c All patients with grade 3 or 4 adverse events
d Although uric acid elevation occurred in only 1 patient (<5%), this adverse 
event was listed because it was grade 3
Adverse event All gradesb Grade 3/4c
Overall adverse events 24 (88.9) 10 (37.0)
Fever 13 (48.1) 0 (0.0)
AST elevation 13 (48.1) 5 (18.5)
ALT elevation 12 (44.4) 2 (7.4)
Leukopenia 7 (25.9) 3 (11.1)
Rash 4 (14.8) 0 (0.0)
Neutropenia 4 (14.8) 3 (11.1)
Thrombocytopenia 3 (11.1) 2 (7.4)
Blood bilirubin elevation 2 (7.4) 1 (3.7)
Creatinine elevation 2 (7.4) 0 (0.0)
Upper respiratory infection 2 (7.4) 0 (0.0)
Uric acid elevation 1 (3.7)d 1 (3.7)
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rash (14.8%), neutropenia (14.8 %), and thrombocytope-
nia (11.1%). Of note, most TRAEs were grade 1–2; grade 
3–4 TRAEs were reported in 37.0% (10/27) of patients, 
including AST elevation (18.5%), leucopenia (11.1%), 
neutropenia (11.1%), ALT elevation (7.4%), thrombocyto-
penia (7.4%).
Serious adverse events were reported in 3 patients 
(11.1%). Of these, during the second cycle of CPT treat-
ment, 1 patient experienced treatment-related grade 3 
ALT elevation and grade 4 AST elevation, which were 
alleviated and resolved within 1  week of treatment dis-
continuation, and was given symptomatic treatments 
such as medications to protect hepatocytes from oxida-
tive and inflammatory damages (e.g., glutathione, poly-
ene phosphatidylcholine). Two patients had either a fever 
during the second cycle of treatment or a lung infection 
at the end of the first cycle, both of which were deemed 
unrelated to CPT treatment and resolved by sympto-
matic therapies (e.g., antipyretics, antibiotics, antifungal 
agents), respectively.
Adverse events caused treatment discontinuation in 4 
patients. Of these, 2 patients experienced either liver dys-
function or lung infection, as described above. In addi-
tion, 1 patient experienced treatment-related grade 3 
elevation of AST, ALT, and bilirubin during the second 
cycle of CPT treatment, and 1 patient experienced treat-
ment-unrelated grade 1 diarrhea and grade 1 fever during 
the second cycle of treatment.
Finally, 18 patients were evaluated for serum levels 
of anti-CPT antibodies; IgG and IgM antibodies were 
detected in 2 (11.1%) and 5 (27.8%) patients, respectively. 
However, no association was observed between serum 
anti-CPT level and therapeutic response (either ORR or 
CBR) or adverse events.
Discussion
In this phase II study, single-agent CPT at a well tolerated 
dose (2.5 mg/kg per day) exhibited a response in patients 
with RRMM. In the past decade, novel treatments 
for patients newly diagnosed with MM have substan-
tially improved outcomes; however, nearly all patients 
who respond to initial therapies eventually relapse 
and become refractory to current treatments, includ-
ing new drugs [1]. The prognosis of these patients with 
RRMM remains dismal. Therefore, new and more effec-
tive therapies are urgently needed. In this phase II trial, 
CPT as a single-agent therapy showed promising activ-
ity: RRMM patients who had been aggressively treated 
previously (median, three prior therapies) had a 33.3% 
ORR and a 48.1% CBR. Interestingly, CPT was also effec-
tive for RRMM patients who had received prior regimens 
containing new anti-MM agents, including bortezomib 
(ORR, 51.9%) and bortezomib plus IMiDs (ORR, 33.3%). 
Thus, the present study showed activity of single-agent 
CPT in the treatment of MM.
In preclinical settings, pro-apoptotic receptor agonists 
(PARAs) have shown potent and selective anti-tumor 
activity; however, few clinical studies of PARAs have 
reported activity in the treatment of patients with can-
cer, including MM. For example, Ashkenazi and Herbst 
[9] summarized that rhApo2L/TRAIL and other PARAs 
had synergistic effects when combined with cytotoxic 
agents, including irinotecan, camptothecin, 5-fluoroura-
cil, carboplatin, paclitaxel, doxorubicin, and gemcitabine. 
Additionally, the combination of Apo2L/TRAIL and 
bortezomib led to enhanced activity in the induction of 
apoptosis in cell lines of a variety of solid tumors [10–12] 
and hematologic malignancies [13–15]. To this end, bort-
ezomib up-regulates DR4/DR5 expression while reducing 
cellular FLICE (FADD-like IL-1β-converting enzyme)-
inhibitory protein (c-FLIP) levels, thereby effectively 
overcoming Apo2L/TRAIL resistance in MM cells [16]. 
However, HGS-ETR1 (mapatumumab, a DR4 agonistic 
monoclonal antibody [17]), when administrated in com-
bination with bortezomib and when compared with bort-
ezomib alone, has failed to improve outcomes of patients 
with advanced MM.
In patients with MM, high serum β2-microglobulin lev-
els have been reported to be associated with poor prog-
nosis. In the study by Bergsagel [18], 66.7% of patients 
with higher β2-microglobulin levels (i.e.,  ≥3.5  mg/L) 
achieved an MR or better, whereas patients with lower 
β2-microglobulin levels (i.e.,  <3.5  mg/L) had a CBR of 
only 28.6%. These findings suggested that CPT might 
benefit MM patients who have higher baseline levels of 
serum β2-microglobulin, which is a well-established bio-
marker for poor prognosis of this disease [18]. In general, 
RRMM patients who have been aggressively pretreated 
usually respond poorly to current regimens, including 
the new drugs (e.g., proteasome inhibitors and IMiDs). 
However, in our study, we observed an interesting trend, 
namely that, after CPT treatment, both ORR and CBR 
were notably higher in patients who had received more 
than three prior treatments than in patients who had 
received three or fewer prior treatments (ORR, 46.2% vs. 
21.4%; CBR, 61.5% vs. 35.7%). We observed similar results 
when we compared response rates between the sub-
groups of patients who had been previously treated with 
bortezomib (ORR, 42.9%; CBR, 57.1%) or bortezomib 
plus IMiDs (ORR, 33.3%; CBR, 55.5%) and those who 
had not received prior bortezomib treatment (ORR, 23.1; 
CBR, 38.5%). One possibility for not observing cross-
resistance between CPT and current anti-MM agents is 
that CPT primarily targets DR4 and DR5 to induce apop-
tosis through activation of the extrinsic apoptotic path-
way, whereas these agents (e.g., bortezomib and IMiDs) 
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act mostly via the mitochondria-mediated intrinsic apop-
totic pathway. Moreover, a potential explanation for the 
likelihood of better responses to CPT in patients who 
received prior bortezomib is that this agent might modu-
late the signaling molecules (e.g., DR4/DR5 [18]) related 
to the extrinsic apoptotic pathway, thereby sensitizing 
MM cells to CPT that targets this pathway. The differ-
ences in the response rates (both ORR and CBR) between 
those subgroups of patients with different baseline char-
acteristics were not statistically significant, most likely 
because of the small sample size; thus, further studies are 
needed to validate these preliminary but interesting find-
ings. It is too soon as well to draw any conclusions about 
which subsets of RRMM patients would likely benefit 
more from single-agent CPT treatment.
In this phase II study, in addition to elevated ALT 
and AST levels and fever, which were most frequently 
observed in the phase I study, the most common adverse 
events were leucopenia, neutropenia, thrombocytope-
nia, and rash. The reason for the common hematologic 
adverse events is most likely due to RRMM itself, which 
often causes hematologic abnormalities. While gastroin-
testinal adverse events and fever were very common in 
an earlier trial of rhApo2L/TRAIL in patients with solid 
tumors [19], elevated AST and ALT levels and fever were 
more common in the present cohort of RRMM patients 
who received single-agent CPT. One possible reason is 
that in our phase II study, patients received prolonged 
treatment with CPT (i.e., 14 days for each cycle), whereas 
in the phase I trial, patients received rhApo2L/TRAIL for 
only 5  days for each cycle. In the clinical development 
of PARAs, liver toxicity has been a major concern [20]. 
In our study, more than half of patients who received 
single-agent CPT experienced elevated AST and/or 
ALT levels. However, it is noteworthy that most of these 
hepatic adverse events were grade 1 or 2, and nearly all 
were manageable with symptomatic treatments and/or 
discontinuation of CPT. Interestingly, most patients with 
elevated AST levels had normal ALT levels, but this was 
often accompanied by elevated LDH levels. This phe-
nomenon was usually observed during the first cycle of 
CPT treatment and very rarely afterwards. AST levels 
returned to normal or near-normal within 1 week; LDH 
levels declined more slowly, to normal or near-normal 
within 2 weeks. Interestingly, patients with transient ele-
vation of AST levels and/or LDH levels but normal ALT 
levels were more likely to achieve an MR or better, sug-
gesting that AST elevation with normal ALT levels might 
not be associated with liver toxicity but rather tumor 
lysis in response to CPT treatment [21]. In contrast to 
transient AST elevation that peaked at day 2 or day 3 of 
the first cycle and then declined quickly, ALT elevation 
was more sustained during the CPT dosing period but 
declined and eventually recovered after discontinua-
tion of CPT. Most patients (80.0%) had grades 1–2 ALT 
elevation, with normal bilirubin level. Only two patients 
discontinued CPT treatment because of liver toxicity; of 
these, one patient had grade 4 AST elevation and grade 
3 ALT elevation, which was reported as a serious adverse 
event, and another patient had grade 3 elevation of AST, 
ALT, and bilirubin, both of which occurred during the 
second cycle of CPT treatment. Of note, in both cases, 
these liver adverse events resolved after discontinuation 
of CPT. Therefore, although patients in our study com-
monly experienced elevated AST and ALT levels, the 
elevated levels were mostly mild or moderate and all 
manageable. Together, these results suggest that single-
agent CPT is well tolerated by patients with RRMM.
Our study does, however, have limitations. First, thera-
peutic response (i.e., ORR and CBR), rather than the gold 
standard endpoint overall survival, was selected as the 
primary outcome to evaluate efficacy of single-agent CPT 
in patients with RRMM. Second, CPT was administered 
for a relatively short period of time (only two 21-day 
cycles). Third, the follow-up time, which ended after the 
second cycle of CPT treatment, was also short. Collec-
tively, these limitations prevent this study from providing 
more definitive evidence for the efficacy of single-agent 
CPT on RRMM. For example, whether longer treatment 
(e.g., increasing the number of intervention cycles) with 
single-agent CPT would be more beneficial while not 
increasing toxicity is still unknown. More importantly, 
whether single-agent CPT would improve long-term 
outcomes (e.g., progression-free survival, duration of 
response, or overall survival) of patients with RRMM is 
also still unknown.
Conclusions
This phase II study provides the first evidence support-
ing the promising therapeutic activity of single-agent 
CPT in the treatment of RRMM patients, including those 
who were aggressively treated previously with current 
regimens containing novel agents, such as bortezomib 
or IMiDs. It also demonstrated that CPT at the dose of 
2.5 mg/kg, given once daily for 14 days per cycle for two 
cycles, was well tolerated. Although mild and moderate 
hepatic adverse events were relatively common, nearly 
all were manageable. Therefore, the single-agent CPT 
therapy and the regimens that combine CPT with first-
line anti-MM agents (e.g., bortezomib and IMiDs) war-
rant further clinical investigation. Accordingly, a phase 
III trial to further develop CPT as a single-agent therapy 
and as part of combination therapies for RRMM is cur-
rently ongoing.
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